nach oben

Die Dermatologie

Erschienen in:

01.01.2004 | Weiterbildung: Zertifizierte Fortbildung

Androgenetische Alopezie

verfasst von: Prof. Dr. R. Hoffmann

Erschienen in: Die Dermatologie | Ausgabe 1/2004

Einloggen, um Zugang zu erhalten

Zusammenfassung

Die androgenetische Alopezie ist bei Frauen und Männern die häufigste Form von Haarverlust. Wenngleich sich der Haarausfall bei Frau und Mann klinisch unterschiedlich manifestiert, so sind dennoch die zugrunde liegenden, zur Alopezie führenden Pathomechanismen dieselben. Es kann davon ausgegangen werden, dass aufgrund genetischer Prägung bestimmte Haarfollikel am Kapillitium eine verstärkte Sensitivität gegenüber Androgenen aufweisen. Die Forschungsergebnisse der letzten Jahre haben eine Vielzahl pathophysiologisch, diagnostisch und therapeutisch bedeutsamer Erkenntnisse hervorgebracht, deren klinisch relevante Aspekte und Neuerungen in dieser Übersicht dargestellt werden.

Andersson S, Bishop RW, Russell DW (1989) Expression cloning and regulation of steroid 5 alpha-reductase, an enzyme essential for male sexual differentiation. J Biol Chem 264:16249–16255PubMed

Andersson S, Russell DW (1990) Structural and biochemical properties of cloned and expressed human and rat steroid 5 alpha-reductases. Proc Natl Acad Sci USA 87:3640–3644PubMed

Arai A, von Hintzenstern J, Kiesewetter F et al. (1990) In vitro effects of testosterone, dihydrotestosterone and estradiol on cell growth of human hair bulb papilla cells and hair root sheath fibroblasts. Acta Derm Venereol 70:338–341PubMed

Aram H (1987) Treatment of female androgenetic alopecia with cimetidine. Int J Dermatol 26:128–130PubMed

Battmann T, Bonfils A, Branche C et al. (1994) RU 58841, a new specific topical antiandrogen: a candidate of choice for the treatment of acne, androgenetic alopecia and hirsutism. J Steroid Biochem Mol Biol 48:55–60CrossRefPubMed

Bergfeld WF (1995) Androgenetic alopecia: an autosomal dominant disorder. Am J Med 98:95S–98SCrossRefPubMed

Birch MP, Messenger AG (2001) Genetic factors predispose to balding and non-balding in men. Eur J Dermatol 11:309–314PubMed

Brenner S, Matz H (1999) Improvement in androgenetic alopecia in 53–76-year-old men using oral finasteride. Int J Dermatol 38:928–930CrossRefPubMed

Buhl AE (1991) Minoxidil’s action in hair follicles. J Invest Dermatol 96:73S–74SPubMed

10.

Buhl AE, Conrad SJ, Waldon DJ, Brunden MN (1993) Potassium channel conductance as a control mechanism in hair follicles. J Invest Dermatol 101:148S–152SPubMed

11.

Buhl AE, Waldon DJ, Baker CA, Johnson GA (1990) Minoxidil sulfate is the active metabolite that stimulates hair follicles. J Invest Dermatol 95:553–557PubMed

12.

Buhl AE, Waldon DJ, Conrad SJ et al. (1992) Potassium channel conductance: a mechanism affecting hair growth both in vitro and in vivo. J Invest Dermatol 98:315–319PubMed

13.

Carey AH, Chan KL, Short F et al. (1993) Evidence for a single gene effect causing polycystic ovaries and male pattern baldness. Clin Endocrinol (Oxf) 38:653–658

14.

Carey AH, Waterworth D, Patel K et al. (1994) Polycystic ovaries and premature male pattern baldness are associated with one allele of the steroid metabolism gene CYP17. Hum Mol Genet 3:1873–1876PubMed

15.

Cash TF (1992) The psychological effects of androgenetic alopecia in men. J Am Acad Dermatol 26:926–931PubMed

16.

Cash TF, Price VH, Savin RC (1993) Psychological effects of androgenetic alopecia on women: comparisons with balding men and with female control subjects. J Am Acad Dermatol 29:568–575PubMed

17.

Devine BL, Fife R, Trust PM (1977) Minoxidil for severe hypertension after failure of other hypotensive drugs. Br Med J 2:667–669PubMed

18.

Diani AR, Mills CJ (1994) Immunocytochemical localization of androgen receptors in the scalp of the stumptail macaque monkey, a model of androgenetic alopecia. J Invest Dermatol 102:511–514PubMed

19.

Diani AR, Mulholland MJ, Shull KL et al. (1992) Hair growth effects of oral administration of finasteride, a steroid 5 alpha-reductase inhibitor, alone and in combination with topical minoxidil in the balding stumptail macaque. J Clin Endocrinol Metab 74:345–350PubMed

20.

Ekoe JM, Burckhardt P, Ruedi B (1980) Treatment of hirsutism, acne and alopecia with cyproterone acetate. Dermatologica 160:398–404PubMed

21.

Ellis JA, Stebbing M, Harrap SB (1998) Genetic analysis of male pattern baldness and the 5alpha-reductase genes. J Invest Dermatol 110:849–853CrossRefPubMed

22.

Ellis JA, Stebbing M, Harrap SB (1999) Insulin gene polymorphism and premature male pattern baldness in the general population. Clin Sci (Lond) 96:659–662

23.

Ellis JA, Stebbing M, Harrap SB (2001) Polymorphism of the androgen receptor gene is associated with male pattern baldness. J Invest Dermatol 116:452–455CrossRefPubMed

24.

Ferriman D, Purdie AW (1979) The inheritance of polycystic ovarian disease and a possible relationship to premature balding. Clin Endocrinol (Oxf) 11:291–300

25.

Gleeson MJ, Connolly J, Grainger R (1993) Self-castration as treatment for alopecia [see comments]. Br J Urol 71:614–615PubMed

26.

Gormley GJ, Stoner E, Rittmaster RS et al. (1990) Effects of finasteride (MK-906), a 5 alpha-reductase inhibitor, on circulating androgens in male volunteers. J Clin Endocrinol Metab 70:1136–1141PubMed

27.

Ha SJ, Kim JS, Myung JW et al. (2003) Analysis of genetic polymorphisms of steroid 5alpha-reductase type 1 and 2 genes in Korean men with androgenetic alopecia. J Dermatol Sci 31:135–141CrossRefPubMed

28.

Hamilton JB (1942) Male hormone stimulation as a prerequisite and an incitement in common baldness. Am J Anat 71:451–453

29.

Hamilton JB (1951) Patterned loss of hair in man: types and incidence. Ann N Y Acad Sci 53:708–728

30.

Happle R, Hoffmann R (1999) Absence of male-pattern baldness in men with X-linked recessive ichthyosis? A hypothesis to be challenged. Dermatology 198:231–232CrossRefPubMed

31.

Hautala T, Heikkinen J, Kivirikko KI, Myllyla R (1992) Minoxidil specifically decreases the expression of lysine hydroxylase in cultured human skin fibroblasts. Biochem J 283:51–54PubMed

32.

Hibberts NA, Messenger AG, Randall VA (1996) Dermal papilla cells derived from beard hair follicles secrete more stem cell factor (SCF) in culture than scalp cells or dermal fibroblasts. Biochem Biophys Res Commun 222:401–405CrossRefPubMed

33.

Hiort O, Holterhus PM, Nitsche EM (1998) Physiology and pathophysiology of androgen action. Baillieres Clin Endocrinol Metab 12:115–132PubMed

34.

Hoffmann R (2001) TrichoScan: combining epiluminescence microscopy with digital image analysis for the measurement of hair growth in vivo. Eur J Dermatol 11:362–368PubMed

35.

Hoffmann R (2002) Male androgenetic alopecia. Clin Exp Dermatol 27:373–382CrossRefPubMed

36.

Hoffmann R (2003) Steroidogenic isoenzymes in human hair and their potential role in androgenetic alopecia. Dermatology 206:85–95CrossRefPubMed

37.

Hoffmann R, Niiyama S, Huth A et al. (2002) 17alpha-estradiol induces aromatase activity in intact human anagen hair follicles ex vivo. Exp Dermatol 11:376–380CrossRefPubMed

38.

Hoffmann R, Rot A, Niiyama S, Billich A (in press) Steroid sulfatase activity in the human hair follicle concentrates in the dermal papilla- possible involvement in local androgen metabolism. J Invest Dermatol 114

39.

Horton R, Pasupuletti V, Antonipillai I (1993) Androgen induction of steroid 5 alpha-reductase may be mediated via insulin-like growth factor-I. Endocrinology 133:447–451PubMed

40.

Imperato-McGinley J, Peterson RE, Gautier T, Sturla E (1979) Male pseudohermaphroditism secondary to 5 alpha-reductase deficiency—a model for the role of androgens in both the development of the male phenotype and the evolution of a male gender identity. J Steroid Biochem 11:637–645CrossRefPubMed

41.

Itami S, Sonoda T, Kurata S, Takayasu S (1994) Mechanism of action of androgen in hair follicles. J Dermatol Sci 7 [Suppl]:S98–103

42.

Jenkins EP, Andersson S, Imperato-McGinley J et al. (1992) Genetic and pharmacological evidence for more than one human steroid 5 alpha-reductase. J Clin Invest 89:293–300PubMed

43.

Kaufman KD (1996) Androgen metabolism as it affects hair growth in androgenetic alopecia. Dermatol Clin 14:697–711PubMed

44.

Kaufman KD (1999) Finasteride, 1 mg (Propecia), is the optimal dose for the treatment of men with male pattern hair loss. Arch Dermatol 135:989–990CrossRefPubMed

45.

Kaufman KD (2002) Long-term (5-year) multinational experience with finasteride 1 mg in the treatment of men with androgenetic alopecia. Eur J Dermatol 12:38–49PubMed

46.

Kaufman KD, Olsen EA, Whiting D et al. (1998) Finasteride in the treatment of men with androgenetic alopecia. Finasteride Male Pattern Hair Loss Study Group. J Am Acad Dermatol 39:578–589PubMed

47.

Kaufman KD, Olsen EA, Whiting D et al. (1998) Finasteride in the treatment of men with androgenetic alopecia. Finasteride Male Pattern Hair Loss Study Group. J Am Acad Dermatol 39:578–589PubMed

48.

Khandpur S, Suman M, Reddy BS (2002) Comparative efficacy of various treatment regimens for androgenetic alopecia in men. J Dermatol 29:489–498PubMed

49.

König A, Happle R, Tchitcherina E et al. (2000) An X-linked gene involved in androgenetic alopecia: a lesson to be learned from adrenoleukodystrophy. Dermatology 200:213–218CrossRefPubMed

50.

Küster W, Happle R (1984) The inheritance of common baldness: two B or not two B? J Am Acad Dermatol 11:921–926PubMed

51.

Lachgar S, Charveron M, Sarraute J et al. (1999) Anti-androgens and estrogens: modulators of VEGF expression in cultured hair dermal papilla cells. Exp Dermatol 8:336–338PubMed

52.

Ludwig E (1977) Classification of the types of androgenetic alopecia (common baldness) occurring in the female sex. Br J Dermatol 97:247–254PubMed

53.

Matias JR, Malloy V, Orentreich N (1989) Animal models of androgen-dependent disorders of the pilosebaceous apparatus. 1. The androchronogenetic alopecia (AGA) mouse as a model for male-pattern baldness. Arch Dermatol Res 281:247–253PubMed

54.

Matias JR, Orentreich N (1988) The effect of testosterone, cyproterone acetate, and minoxidil on hair loss in the androchronogenetic alopecia mouse. Clin Dermatol 6:169–176PubMed

55.

Michelet JF, Commo S, Billoni N et al. (1997) Activation of cytoprotective prostaglandin synthase-1 by minoxidil as a possible explanation for its hair growth-stimulating effect. J Invest Dermatol 108:205–209PubMed

56.

Mortimer CH, Rushton H, James KC (1984) Effective medical treatment of common baldness in women. Clin Exp Dermatol 9:342–350PubMed

57.

Niiyama S, Happle R, Hoffmann R (2001) Influence of estrogens on the androgen metabolism in different subunits of human hair follicles. Eur J Dermatol 11:195–198PubMed

58.

Nowakowski H, Lenz W (1961) Genetic aspects of male hypogonadism. Prog Horm Res 17:53–89

59.

Olsen EA, DeLong ER, Weiner MS (1986) Dose-response study of topical minoxidil in male pattern baldness. J Am Acad Dermatol 15:30–37PubMed

60.

Olsen EA, Dunlap FE, Funicella T et al. (2002) A randomized clinical trial of 5% topical minoxidil versus 2% topical minoxidil and placebo in the treatment of androgenetic alopecia in men. J Am Acad Dermatol 47:377–385CrossRefPubMed

61.

Olsen EA, Weiner MS (1987) Topical minoxidil in male pattern baldness: effects of discontinuation of treatment. J Am Acad Dermatol 17:97–101PubMed

62.

Pan HJ, Wilding G, Uno H et al. (1998) Evaluation of RU58841 as an anti-androgen in prostate PC3 cells and a topical anti-alopecia agent in the bald scalp of stumptailed macaques. Endocrine 9:39–43CrossRefPubMed

63.

Peereboom-Wynia JD, van der Willigen AH, van Joost T, Stolz E (1989) The effect of cyproterone acetate on hair roots and hair shaft diameter in androgenetic alopecia in females. Acta Derm Venereol 69:395–398PubMed

64.

Platz EA, Pollak MN, Willett WC, Giovannucci E (2000) Vertex balding, plasma insulin-like growth factor 1, and insulin-like growth factor binding protein 3. J Am Acad Dermatol 42:1003–1007CrossRefPubMed

65.

Price VH, Menefee E (1996) Quantitative estimation of hair growth: coparative changes in weight and hair count with 5% and 2% minoxidil, placebo and no treatment. In: Neste va D Randall V. (eds) Hair research for the next millenium. Elsevier, Amsterdam, pp 67–72

66.

Price VH, Menefee E, Sanchez M et al. (2002) Changes in hair weight and hair count in men with androgenetic alopecia after treatment with finasteride, 1 mg, daily. J Am Acad Dermatol 46:517–523CrossRefPubMed

67.

Price VH, Menefee E, Strauss PC (1999) Changes in hair weight and hair count in men with androgenetic alopecia, after application of 5% and 2% topical minoxidil, placebo, or no treatment. J Am Acad Dermatol 41:717–721PubMed

68.

Price VH, Roberts JL, Hordinsky M et al. (2000) Lack of efficacy of finasteride in postmenopausal women with androgenetic alopecia. J Am Acad Dermatol 43:768–776CrossRefPubMed

69.

Randall VA, Thornton MJ, Messenger AG (1992) Cultured dermal papilla cells from androgen-dependent human hair follicles (e.g. beard) contain more androgen receptors than those from non-balding areas of scalp. J Endocrinol 133:141–147PubMed

70.

Rhodes L, Harper J, Uno H et al. (1994) The effects of finasteride (Proscar) on hair growth, hair cycle stage, and serum testosterone and dihydrotestosterone in adult male and female stumptail macaques (Macaca arctoides). J Clin Endocrinol Metab 79:991–996PubMed

71.

Rhodes L, Primka R, Berman C et al. (1995) Effects of 1 year treatment with oral MK386, an inhibitor of type 1 5a-reductase, in the stumptailed macaques (Macaca arctoides). J Invest Dermatol ❚:❚ (Abstr.)

72.

Sauter LS, Weibel ER (1971) Morphometric evaluation of skin structures by stereologic methods. Application to testosterone-treated rats. Dermatologica 143:174–183PubMed

73.

Sawaya ME, Blume-Peytavi U, Mullins D et al. (2002) Effects of finasteride on apoptosis and regulation of the human hair cycle. J Cutan Med Surg 6:1–9CrossRefPubMed

74.

Sawaya ME, Price VH (1997) Different levels of 5alpha-reductase type I and II, aromatase, and androgen receptor in hair follicles of women and men with androgenetic alopecia. J Invest Dermatol 109:296–300PubMed

75.

Sawaya ME, Shalita AR (1998) Androgen receptor polymorphisms (CAG repeat lengths) in androgenetic alopecia, hirsutism, and acne. J Cutan Med Surg 3:9–15PubMed

76.

Shapiro J, Price VH (1998) Hair regrowth. Therapeutic agents. Dermatol Clin 16:341–356PubMed

77.

Shum KW, Cullen DR, Messenger AG (2002) Hair loss in women with hyperandrogenism: four cases responding to finasteride. J Am Acad Dermatol 47:733–739CrossRefPubMed

78.

Signorello LB, Wuu J, Hsieh C et al. (1999) Hormones and hair patterning in men: a role for insulin-like growth factor 1? J Am Acad Dermatol 40:200–203PubMed

79.

Sonoda T, Kurata S, Asada Y, Takayasu S (1998) Message of protease nexin-1 is expressed in human dermal papilla cells and is affected by androgens. J Invest Dermatol 100:612 (Abst.)

80.

Spindler JR, Data JL (1992) Female androgenetic alopecia: a review. Dermatol Nurs 4:93–99PubMed

81.

Sprecher E, Shalata A, Dabhah K et al. (2000) Androgenetic alopecia in heterozygous carriers of a mutation in the human hairless gene. J Am Acad Dermatol 42:978–982CrossRefPubMed

82.

Stough DB, Rao NA, Kaufman KD, Mitchell C (2002) Finasteride improves male pattern hair loss in a randomized study in identical twins. Eur J Dermatol 12:32–37PubMed

83.

Takashima I, Montagna W (1971) Studies of common baldness of the stump-tailed macaque (Macaca speciosa). VI. The effect of testosterone on common baldness. Arch Dermatol 103:527–534CrossRefPubMed

84.

Thigpen AE, Davis DL, Milatovich A et al. (1992) Molecular genetics of steroid 5 alpha-reductase 2 deficiency. J Clin Invest 90:799–809PubMed

85.

Thornton MJ, Hamada K, Messenger AG, Randall VA (1998) Androgen-dependent beard dermal papilla cells secrete autocrine growth factor(s) in response to testosterone unlike scalp cells. J Invest Dermatol 111:727–732CrossRefPubMed

86.

Tosti A, Camacho-Martinez F, Dawber R (1999) Management of androgenetic alopecia. J Eur Acad Dermatol Venereol 12:205–214CrossRefPubMed

87.

Trueb RM, Meyer JC (2000) Male-pattern baldness in men with X-linked recessive ichthyosis. Dermatology 200:247–249CrossRefPubMed

88.

Uno H, Cappas A, Brigham P (1987) Action of topical minoxidil in the bald stump-tailed macaque. J Am Acad Dermatol 16:657–668PubMed

89.

van der Donk J, Passchier J, Dutree-Meulenberg RO et al. (1991) Psychologic characteristics of men with alopecia androgenetica and their modification. Int J Dermatol 30:22–28PubMed

90.

van der Donk J, Passchier J, Knegt-Junk C et al. (1991) Psychological characteristics of women with androgenetic alopecia: a controlled study. Br J Dermatol 125:248–252PubMed

91.

Van Neste D, De Brouwer B, Dumortier M (1991) Reduced linear hair growth rates of vellus and of terminal hairs produced by human balding scalp grafted onto nude mice. Ann N Y Acad Sci 642:480–482PubMed

92.

Vanderveen EE, Ellis CN, Kang S et al. (1984) Topical minoxidil for hair regrowth. J Am Acad Dermatol 11:416–421PubMed

93.

Vexiau P, Chaspoux C, Boudou P et al. (2002) Effects of minoxidil 2% vs. cyproterone acetate treatment on female androgenetic alopecia: a controlled, 12-month randomized trial. Br J Dermatol 146:992–999CrossRefPubMed

94.

Wahe M, Antonipillai I, Horton R (1993) Effects of transforming growth factor beta and epidermal growth factor on steroid 5 alpha-reductase activity in genital skin fibroblasts. Mol Cell Endocrinol 98:55–59CrossRefPubMed

95.

Wester RC, Maibach HI, Guy RH, Novak E (1984) Minoxidil stimulates cutaneous blood flow in human balding scalps: pharmacodynamics measured by laser Doppler velocimetry and photopulse plethysmography. J Invest Dermatol 82:515–517PubMed

96.

Whiting DA, Olsen EA, Savin R et al. (2003) Efficacy and tolerability of finasteride 1 mg in men aged 41 to 60 years with male pattern hair loss. Eur J Dermatol 13:150–160PubMed

97.

Whiting DA, Waldstreicher J, Sanchez M, Kaufman KD (1999) Measuring reversal of hair miniaturization in androgenetic alopecia by follicular counts in horizontal sections of serial scalp biopsies: results of finasteride 1 mg treatment of men and postmenopausal women. J Investig Dermatol Symp Proc 4:282–284PubMed

98.

Williamson D, Gonzalez M, Finlay AY (2000) The effect of hair loss on quality of life. J Eur Acad Dermatol Venereol 15:137–139CrossRefPubMed

99.

Wilton L, Pearce G, Edet E et al. (1996) The safety of finasteride used in benign prostatic hypertrophy: a non- interventional observational cohort study in 14,772 patients. Br J Urol 78:379–384PubMed

100.

Yu DW, Yang T, Sonoda T et al. (1995) Message of nexin 1, a serine protease inhibitor, is accumulated in the follicular papilla during anagen of the hair cycle. J Cell Sci 108:3867–3874PubMed

Titel: Androgenetische Alopezie
verfasst von: Prof. Dr. R. Hoffmann
Publikationsdatum: 01.01.2004
Verlag: Springer-Verlag
Erschienen in: Die Dermatologie / Ausgabe 1/2004
Print ISSN: 2731-7005
Elektronische ISSN: 2731-7013
DOI: https://doi.org/10.1007/s00105-003-0673-4

Leitlinien kompakt für die Dermatologie

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Dermatologie

16.04.2024 | Infektiologie | Nachrichten

Update Dermatologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

Androgenetische Alopezie

Zusammenfassung

Leitlinien kompakt für die Dermatologie

Neu im Fachgebiet Dermatologie

Kein Abstrich bei chronischen Wunden ohne Entzündungszeichen!

Vitiligo: Prävalenz steigt und viele Erkrankte werden spät behandelt

Dupilumab ist mit kutanen T-Zell-Lymphomen assoziiert

Chemotherapie mit Hindernissen

Update Dermatologie

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

Zusammenfassung

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 1/2004

Disseminierte eruptive Syringome bei Down-Syndrom

Blick zurück nach vorn

Kutane Infektion mit Mycobacterium marinum

Allergische Berufsdermatosen

3-fach punkten unter cme.springer.de

Rechtliche Aspekte der ärztlichen Fortbildung

Leitlinien kompakt für die Dermatologie

Neu im Fachgebiet Dermatologie

Kein Abstrich bei chronischen Wunden ohne Entzündungszeichen!

Vitiligo: Prävalenz steigt und viele Erkrankte werden spät behandelt

Dupilumab ist mit kutanen T-Zell-Lymphomen assoziiert

Chemotherapie mit Hindernissen

Update Dermatologie